Biotron Limited Stock Price To Sales
| BITRF Stock | USD 0.01 0.00 0.00% |
Fundamental analysis of Biotron allows traders to better anticipate movements in Biotron's stock price by examining its financial health and performance throughout various phases of its business cycle.
Biotron |
Biotron Limited Company Price To Sales Analysis
Biotron's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Biotron Price To Sales | 11.17 X |
Most of Biotron's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotron Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Biotron Limited has a Price To Sales of 11.1691 times. This is 47.81% lower than that of the Healthcare sector and 88.65% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 2.2% higher than that of the company.
Biotron Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotron's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biotron could also be used in its relative valuation, which is a method of valuing Biotron by comparing valuation metrics of similar companies.Biotron is currently under evaluation in price to sales category among its peers.
Biotron Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.56 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 15.31 M | |||
| Shares Outstanding | 901.94 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Price To Earning | (3.04) X | |||
| Price To Book | 23.61 X | |||
| Price To Sales | 11.17 X | |||
| Revenue | 1.56 M | |||
| Gross Profit | 1.56 M | |||
| EBITDA | (2.73 M) | |||
| Net Income | (2.78 M) | |||
| Cash And Equivalents | 1.74 M | |||
| Total Debt | 77.24 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 2.35 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.44 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 10 | |||
| Beta | -1.2 | |||
| Market Capitalization | 18.67 M | |||
| Total Asset | 1.91 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 3 M | |||
| Current Asset | 3 M | |||
| Net Asset | 1.91 M |
About Biotron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotron Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotron Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Biotron Pink Sheet
Biotron financial ratios help investors to determine whether Biotron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotron with respect to the benefits of owning Biotron security.